<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Iatrogenic <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> causes recurrent morbidity in most people with type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> and many with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, and it is sometimes fatal </plain></SENT>
<SENT sid="1" pm="."><plain>The barrier of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> generally precludes maintenance of euglycemia over a lifetime of <z:mp ids='MP_0002055'>diabetes</z:mp> and thus precludes full realization of euglycemia's long-term benefits </plain></SENT>
<SENT sid="2" pm="."><plain>While the clinical presentation is often characteristic, particularly for the experienced individual with <z:mp ids='MP_0002055'>diabetes</z:mp>, the neurogenic and neuroglycopenic symptoms of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> are nonspecific and relatively insensitive; therefore, many episodes are not recognized </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0001943'>Hypoglycemia</z:hpo> can result from exogenous or endogenous insulin excess alone </plain></SENT>
<SENT sid="4" pm="."><plain>However, iatrogenic <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> is typically the result of the interplay of absolute or relative insulin excess and compromised <z:chebi fb="105" ids="17234">glucose</z:chebi> counterregulation in type 1 and advanced type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>Decrements in insulin, increments in glucagon, and, absent the latter, increments in <z:chebi fb="2" ids="28918">epinephrine</z:chebi> stand high in the hierarchy of redundant <z:chebi fb="105" ids="17234">glucose</z:chebi> counterregulatory factors that normally prevent or rapidly correct <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>In insulin-deficient <z:mp ids='MP_0002055'>diabetes</z:mp> (exogenous) insulin levels do not decrease as <z:chebi fb="105" ids="17234">glucose</z:chebi> levels fall, and the combination of deficient glucagon and <z:chebi fb="2" ids="28918">epinephrine</z:chebi> responses causes defective <z:chebi fb="105" ids="17234">glucose</z:chebi> counterregulation </plain></SENT>
<SENT sid="7" pm="."><plain>Reduced sympathoadrenal responses cause <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> unawareness </plain></SENT>
<SENT sid="8" pm="."><plain>The concept of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo>-associated <z:e sem="disease" ids="C0393911" disease_type="Disease or Syndrome" abbrv="">autonomic failure</z:e> in <z:mp ids='MP_0002055'>diabetes</z:mp> posits that recent antecedent <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> causes both defective <z:chebi fb="105" ids="17234">glucose</z:chebi> counterregulation and <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> unawareness </plain></SENT>
<SENT sid="9" pm="."><plain>By shifting glycemic thresholds for the sympathoadrenal (including <z:chebi fb="2" ids="28918">epinephrine</z:chebi>) and the resulting neurogenic responses to lower plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> concentrations, antecedent <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> leads to a vicious cycle of <z:hpo ids='HP_0001988'>recurrent hypoglycemia</z:hpo> and further impairment of <z:chebi fb="105" ids="17234">glucose</z:chebi> counterregulation </plain></SENT>
<SENT sid="10" pm="."><plain>Thus, short-term avoidance of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> reverses <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> unawareness in most affected patients </plain></SENT>
<SENT sid="11" pm="."><plain>The clinical approach to minimizing <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> while improving glycemic control includes 1) addressing the issue, 2) applying the principles of aggressive glycemic therapy, including flexible and individualized drug regimens, and 3) considering the risk factors for iatrogenic <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>The latter include factors that result in absolute or relative insulin excess: drug dose, timing, and type; patterns of food ingestion and exercise; interactions with alcohol and other drugs; and altered sensitivity to or clearance of insulin </plain></SENT>
<SENT sid="13" pm="."><plain>They also include factors that are clinical surrogates of compromised <z:chebi fb="105" ids="17234">glucose</z:chebi> counterregulation: endogenous insulin deficiency; history of severe <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo>, <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> unawareness, or both; and aggressive glycemic therapy per se, as evidenced by lower HbA(1c) levels, lower glycemic goals, or both </plain></SENT>
<SENT sid="14" pm="."><plain>In a patient with <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> unawareness (which implies <z:hpo ids='HP_0001988'>recurrent hypoglycemia</z:hpo>) a 2- to 3-week period of scrupulous avoidance of <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> is advisable </plain></SENT>
<SENT sid="15" pm="."><plain>Pending the prevention and cure of <z:mp ids='MP_0002055'>diabetes</z:mp> or the development of methods that provide <z:chebi fb="105" ids="17234">glucose</z:chebi>-regulated insulin replacement or secretion, we need to learn to replace insulin in a much more physiological fashion, to prevent, correct, or compensate for compromised <z:chebi fb="105" ids="17234">glucose</z:chebi> counterregulation, or both if we are to achieve near-euglycemia safely in most people with <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>